Clinical Trial Search

Primary: Children's Depression Rating Scale-Revised (CDRS-R) Post Treatment 30 or Last Treatment (in Cases of Early Withdrawal) — 41.8 units on a scale

Primary: 28 Day In-hospital Mortality — 20; 11 participants — p=0.04

Primary: Frequency of Adverse Events — 12; 15; 1; 0 participants

Primary: Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Revaccination — 2.72; 2.27; 2.40 Geometric Mean Fold Rise — p=<0.001

Primary: Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 — 46.1; 44.9; 57.7; 70.9 percentage…

Primary: Number of Participants Reporting Solicited Local and Systemic Adverse Events (AEs) — 7; 5; 4; 0 participants

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 7; 22 participants — p=0.005

Primary: Responders OARSI 2004 at the End of Follow-up — 80.5; 65.8 percentage of responders — p=0.004

Primary: Percentage of Participants With Hb Levels Within 11.0-12.5 Grams Per Deciliter (g/dL) During Evaluation Phase — 31.7 percentage of participants

Primary: Overjet — 0.25; 0.27; 0.28 mm

Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001

Primary: Time-to-progression (TTP) — 5 months

Primary: Change From Baseline to End of Study in Number of Rectal Polyps — -5.4; -1.6; -3.5 polyps — p=0.065

Primary: Weight Gain in Grams Per Day — 24.3; 23.6 grams/day — p=0.05

Primary: The Blood Levels of Calcium at the 24th Month of Following up. — 2.31; 2.33 mmol/L — p=0.117